# Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

> **NCT05431257** · PHASE2 · RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 117 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05431257
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-24
- **Primary completion:** 2031-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2022-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431257, "Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05431257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*